Position Statements

In reaction to the recent statement from Matt Hancock, Secretary of State for Health, it is Pain UK’s position that opioids remain a vital class of medicines to mitigate pain when their use is appropriately monitored by healthcare professionals and patients. Additionally, there is a requirement for up to date education about opioids’ potential risk to health. Download Position Statement …

On the 15th November 2018, Pain UK trustees attended a pharmaceutical company sponsored debate on the use of medicinal cannabis. The event included clinical, regulatory and pharmaceutical experts. Pain UK attendance was in the context of the UK government’s recent decision to reschedule cannabis products1 and interim NHS clinical guidance enabling specialist doctors to prescribe medicinal cannabis2. It is evident that there is significant debate as to the clinical …